Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
948 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07564401 | A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy | recruiting | Phase 1 / Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss(EPIK-B3) | terminated | Phase 3 | 137 | Novartis PharmaceuticalsINDUSTRY | 30 | Sep 10, 2026 |
| clinicaltrials |
| NCT05445843 | Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.(KontRASt-06) | active not recruiting | Phase 2 | 95 | Novartis PharmaceuticalsINDUSTRY | 19 | Sep 10, 2026 | clinicaltrials |
| NCT05552469 | Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases | active not recruiting | Phase 1 | 71 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 10, 2026 | clinicaltrials |
| NCT03040973 | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | active not recruiting | Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 9, 2026 | clinicaltrials |
| NCT05275868 | Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 1 | 41 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT06704269 | Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis | active not recruiting | Phase 1 / Phase 2 | 15 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 4, 2026 | clinicaltrials |
| NCT07604571 | Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer | recruiting | Phase 1 | 194 | Novartis PharmaceuticalsINDUSTRY | 5 | Sep 4, 2026 | clinicaltrials |
| NCT07549516 | A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany(ASC2ADHERE) | recruiting | — | 380 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07354074 | Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP | recruiting | Phase 2 | 50 | Novartis PharmaceuticalsINDUSTRY | 13 | Sep 2, 2026 | clinicaltrials |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | active not recruiting | Phase 3 | 405 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 28, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT06726148 | Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Novartis PharmaceuticalsINDUSTRY | 16 | Aug 27, 2026 | clinicaltrials |
| NCT07117214 | A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers | recruiting | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07630961 | Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07660055 | Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors | recruiting | Phase 1 | 156 | Novartis PharmaceuticalsINDUSTRY | 4 | Aug 27, 2026 | clinicaltrials |
| NCT05456191 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)(ASC4START) | active not recruiting | Phase 3 | 568 | Novartis PharmaceuticalsINDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT02962414 | Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | active not recruiting | Phase 3 | 206 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 21, 2026 | clinicaltrials |
| NCT02386800 | CINC424A2X01B Rollover Protocol | active not recruiting | Phase 4 | 279 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 20, 2026 | clinicaltrials |
| NCT07454850 | A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait | not yet recruiting | — | 400 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 20, 2026 | clinicaltrials |
| NCT03876769 | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients(CASSIOPEIA) | active not recruiting | Phase 2 | 121 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 19, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT05142696 | A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab | active not recruiting | Phase 1 / Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 19, 2026 | clinicaltrials |
| NCT01742299 | Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator | completed | Phase 4 | 155 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT03106779 | Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs | completed | Phase 3 | 233 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 18, 2026 | clinicaltrials |
| NCT05067140 | A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 164 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05853458 | Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors(HU-F-AIM) | terminated | Phase 4 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07770074 | A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients | not yet recruiting | — | 200 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07760714 | A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer Patients | completed | — | 945 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01784068 | Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients(ENESTfreedom) | completed | Phase 2 | 215 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 13, 2026 | clinicaltrials |
| NCT01698905 | Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)(ENESTop) | completed | Phase 2 | 163 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 12, 2026 | clinicaltrials |
| NCT06517758 | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | active not recruiting | Phase 3 | 146 | Novartis PharmaceuticalsINDUSTRY | 18 | Aug 12, 2026 | clinicaltrials |
| NCT06930859 | Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia(ELEGANCE) | recruiting | — | 2,766 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07681258 | A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region(ASC4Young) | not yet recruiting | — | 80 | Novartis PharmaceuticalsINDUSTRY | 0 | Aug 10, 2026 | clinicaltrials |
| NCT06785818 | Long-term Follow up Local Registry Study of Kymriah in South Korea | recruiting | — | 500 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06830720 | A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence(CAROLEEN) | recruiting | — | 3,250 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT07288359 | Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 205 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 30, 2026 | clinicaltrials |
| NCT06075758 | A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer | completed | — | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jul 29, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT04058756 | Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments | active not recruiting | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 17 | Jul 28, 2026 | clinicaltrials |
| NCT05397496 | Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies | active not recruiting | Phase 1 | 61 | Novartis PharmaceuticalsINDUSTRY | 9 | Jul 28, 2026 | clinicaltrials |
| NCT05415072 | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas | active not recruiting | Phase 1 / Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 7 | Jul 28, 2026 | clinicaltrials |
| NCT04939610 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors(LuMIERE) | recruiting | Phase 1 / Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 6 | Jul 24, 2026 | clinicaltrials |
| NCT07697989 | Pluvicto Real-world Investigation in Survival in Metastatic CRPC(PRISM) | not yet recruiting | — | 1,085 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 22, 2026 | clinicaltrials |
| NCT07091019 | A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy(ASC4REAL-2) | recruiting | — | 1,000 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07710716 | A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients(CATTALYST) | active not recruiting | — | 3,000 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT00756509 | Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib | completed | Phase 4 | 34 | Novartis PharmaceuticalsINDUSTRY | 5 | Jul 16, 2026 | clinicaltrials |
| NCT07677254 | A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | — | 17,111 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
Data updated 19 days agoSource updated unknownsource: clinicaltrials